GO:0005528 FK506 binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005528 (FK506 binding) describes the molecular function of binding to FK506, a 23-membered macrolide lactone immunosuppressant.
• FK506-binding proteins (FKBPs) are the primary proteins that carry this function and are conserved from yeast to humans.
• The FKBP-FK506 complex inhibits calcineurin, a calcium/calmodulin-dependent phosphatase, thereby blocking T-cell activation.
• FKBPs are involved in diverse cellular processes including protein folding, apoptosis, calcium homeostasis, and inflammation.
• Dysregulation of FK506 binding is implicated in cancer, male infertility, and neurodegenerative conditions.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models are essential to dissect FKBP gene function and therapeutic potential.
Description
FK506 binding (GO:0005528) is a molecular function defined as the binding to FK506, a 23-membered macrolide lactone immunosuppressant. This function is primarily mediated by the FK506-binding protein (FKBP) family, which includes FKBP12, FKBP12.6, FKBP13, FKBP52, and others. FKBPs are ubiquitous and highly conserved, playing critical roles in protein folding, signal transduction, and immune regulation. The interaction between FK506 and FKBPs is not only central to immunosuppressive therapy but also serves as a key tool in chemical biology to probe calcineurin signaling. Researchers study FK506 binding to understand fundamental cellular processes and to develop novel therapeutics for cancer, inflammation, and infertility. This article provides a comprehensive overview of the genes, mechanisms, and research methods associated with GO:0005528.
FK506 binding At A Glance
| GO ID | GO:0005528 |
|---|---|
| GO term | FK506 binding |
| Ontology | molecular_function |
| Synonym | FK506-sensitive peptidyl-prolyl cis-trans isomerase |
| Major function | Binding to the immunosuppressant FK506, often coupled with peptidyl-prolyl isomerase activity |
| Major proteins | FKBP12, FKBP12.6, FKBP13, FKBP52, and other FKBPs |
| Associated processes | Immunosuppression, protein folding, calcium signaling, apoptosis |
| Disease relevance | Cancer, male infertility, inflammation, neurodegeneration |
What Is GO:0005528?
FK506 binding is the molecular function of selectively interacting with FK506, a macrolide lactone compound. This binding is typically mediated by proteins containing an FKBP domain, which binds FK506 with high affinity. The function is often associated with peptidyl-prolyl cis-trans isomerase activity, but the defining feature is the physical interaction with FK506.
Why Is FK506 binding Important in Cell Biology?
FK506 binding is critically important because it mediates the immunosuppressive effects of FK506 and serves as a paradigm for understanding protein-ligand interactions that regulate signal transduction. The FKBP-FK506 complex inhibits calcineurin, a central phosphatase in T-cell activation, making it a cornerstone of transplant medicine. Beyond immunosuppression, FKBPs are involved in diverse physiological and pathological processes, including cancer progression, apoptosis, and calcium homeostasis. Thus, studying FK506 binding provides insights into basic biology and offers therapeutic opportunities.
• FK506 binding is the molecular basis for the immunosuppressive drug FK506 (tacrolimus) used in organ transplantation.
• FKBPs regulate calcineurin signaling, which is essential for T-cell activation and immune responses.
• FKBP12.6 (FKBP1B) modulates calcium release channels, affecting cardiac and neuronal function.
• FKBP13 (FKBP2) inhibits Bax-induced apoptosis in yeast, linking FK506 binding to cell death pathways.
• FKBP52 (FKBP4) interacts with steroid hormone receptors and is implicated in cancer and neurodevelopment.
• Dysregulation of FKBPs is associated with male infertility due to calcineurin inhibition in sperm.
• FKBPs are targets for anticancer therapy, with ligands being developed as chemotherapeutic agents.
• Conformational instability in FKBP12 has been linked to disease-associated mutations.
• FK506 binding proteins are involved in inflammation-related signaling pathways, offering anti-inflammatory targets.
• CRISPR screens can identify novel FKBPs and their roles in health and disease.
What Happens During FK506 binding?
FK506 Binding and Conformational Change
In simple terms: FK506 binds to FKBP proteins, causing a shape change that allows them to interact with other proteins.
FK506, a macrolide lactone, binds with high affinity to the FKBP domain of FK506-binding proteins. This binding induces a conformational change in the FKBP, creating a composite surface that can interact with target proteins such as calcineurin. The binding is reversible and competitive with other ligands.
Inhibition of Calcineurin Phosphatase Activity
In simple terms: The FKBP-FK506 complex blocks calcineurin, a protein that activates immune cells.
The FKBP12-FK506 complex binds to calcineurin, inhibiting its phosphatase activity. This inhibition prevents the dephosphorylation of NFAT transcription factors, thereby blocking their nuclear translocation and subsequent T-cell activation. This mechanism is the basis for the immunosuppressive effects of FK506.
Regulation of Calcium Homeostasis
In simple terms: FK506 binding proteins help control calcium levels inside cells, which is important for many cellular functions.
FKBP12.6 (FKBP1B) associates with ryanodine receptors and modulates calcium release from intracellular stores. FK506 binding disrupts this interaction, leading to altered calcium homeostasis, which can affect muscle contraction and neuronal signaling.
Modulation of Apoptosis
In simple terms: Some FK506-binding proteins can influence whether cells live or die.
FKBP13 (FKBP2) has been shown to inhibit Bax-induced apoptosis in Saccharomyces cerevisiae, suggesting a role in cell death regulation. The binding of FK506 may interfere with this function, although the exact mechanism remains under investigation.
Key Genes Involved in GO:0005528 FK506 binding
The following genes encode proteins that exhibit FK506 binding activity and are key research targets.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FKBP1A | FKBP12; binds FK506 and inhibits calcineurin | Immunosuppression, cardiac function, cancer |
| FKBP1B | FKBP12.6; regulates ryanodine receptor calcium channels | Cardiac arrhythmias, neuronal signaling |
| FKBP2 | FKBP13; inhibits Bax-induced apoptosis | Apoptosis, yeast models |
| FKBP3 | FKBP25; nuclear FKBP involved in transcription | Cancer, chromatin regulation |
| FKBP4 | FKBP52; interacts with steroid hormone receptors | Cancer, neurodevelopment |
| FKBP5 | FKBP51; regulates glucocorticoid receptor | Depression, inflammation |
| FKBP6 | FKBP36; involved in meiosis | Male infertility |
| FKBP7 | FKBP23; ER-resident, involved in protein folding | ER stress, cancer |
| FKBP8 | FKBP38; anti-apoptotic, interacts with Bcl-2 | Cancer, apoptosis |
| FKBP9 | FKBP60; ER protein, role in calcium homeostasis | Cancer, ER stress |
| FKBP10 | FKBP65; collagen folding | Osteogenesis imperfecta |
| FKBP11 | FKBP19; involved in ER quality control | Cancer, ER stress |
| FKBP14 | FKBP22; collagen modification | Ehlers-Danlos syndrome |
| FKBP15 | FKBP133; actin cytoskeleton regulation | Cell migration |
| FKBP52 | FKBP52; same as FKBP4 | Cancer, steroid signaling |
| PPIL1 | Peptidyl-prolyl isomerase-like 1; binds FK506 | Spliceosome function |
| PPIL2 | Peptidyl-prolyl isomerase-like 2; binds FK506 | Ubiquitination |
How Is FK506 binding Regulated?
FK506 binding activity is regulated at multiple levels. The expression of FKBPs is controlled by various transcription factors, including steroid receptors and stress-responsive factors. Post-translational modifications such as phosphorylation can modulate FKBP activity and interactions. Additionally, the availability of FK506 and its analogs influences the binding function in pharmacological contexts. The interaction between FKBPs and calcineurin is also regulated by calcium/calmodulin signaling.
FK506 binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FKBP1A | Immunosuppression, cardiac hypertrophy | Knockout mouse, cardiomyocyte cell lines |
| FKBP1B | Male infertility, cardiac arrhythmia | Sperm-specific knockout, iPSC-derived cardiomyocytes |
| FKBP2 | Apoptosis resistance in cancer | Yeast knockout, cancer cell lines |
| FKBP4 | Prostate cancer, neurodevelopmental disorders | Knockdown in prostate cancer cells, neuronal cultures |
| FKBP5 | Depression, glucocorticoid resistance | Knockout mouse, lymphoblastoid cell lines |
FK506 Binding in Cancer
FKBPs are frequently overexpressed in various cancers and contribute to tumor progression by regulating cell cycle, apoptosis, and steroid receptor signaling. For example, FKBP52 (FKBP4) enhances androgen receptor activity and is implicated in prostate cancer. Targeting FKBP-FK506 binding with small molecule inhibitors is a promising anticancer strategy.
FK506 Binding and Male Infertility
FK506 binding protein 12.6 (FKBP1B) inhibits sperm-specific calcineurin, and FK506 treatment disrupts calcium and mitochondrial homeostasis in sperm, leading to male infertility. This highlights the importance of FK506 binding in reproductive biology.
FK506 Binding in Neurodegeneration
FKBP12 and FKBP52 are involved in neuronal survival and regeneration. FK506 has neuroprotective effects in animal models, partly through inhibition of calcineurin and modulation of FKBP interactions. Dysregulation of FKBP signaling has been linked to Alzheimer's and Parkinson's diseases.
FK506 Binding in Inflammation
FKBP-FK506 complexes suppress inflammatory signaling pathways by inhibiting calcineurin and NFAT, which are critical for cytokine production. This makes FK506 binding a key target for anti-inflammatory therapies.
From FK506 binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does FKBP1A knockout affect T-cell activation? | Jurkat T-cell line with CRISPR KO |
| How does FKBP1B point mutation affect calcium handling? | iPSC-derived cardiomyocytes with knock-in mutation |
| Can FKBP2 overexpression protect against apoptosis? | Yeast or mammalian cells with overexpression vector |
| What is the interactome of FKBP52? | HEK293T cells with tagged knock-in (APEX2 or BioID) |
| Does FKBP5 knockout alter glucocorticoid response? | Mouse model with conditional KO |
| Can CRISPR screen identify novel FK506-binding proteins? | Genome-wide CRISPR library in cancer cell lines |
How to Study the FK506 binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance | Binding affinity and kinetics | FK506-FKBP interaction studies |
| X-ray crystallography | 3D structure of protein-ligand complex | Mechanistic insights into FKBP-FK506-calcineurin |
| CRISPR knockout screen | Gene essentiality and drug sensitivity | Identifying modifiers of FK506 response |
| RNA-seq | Transcriptional changes | Effect of FK506 on immune cells |
| Proteomics (AP-MS) | Protein-protein interactions | Mapping FKBP interactome |
| Calcium imaging | Intracellular calcium dynamics | FKBP12.6 function in cardiomyocytes |
| Apoptosis assays | Cell death quantification | FKBP13 anti-apoptotic activity |
Biochemical Binding Assays
FK506 binding can be measured using surface plasmon resonance (SPR), isothermal titration calorimetry (ITC), or fluorescence polarization. These methods determine binding affinity and kinetics between FK506 and FKBPs.
Structural Biology
X-ray crystallography and NMR spectroscopy have elucidated the structure of FKBP12 in complex with FK506 and calcineurin, revealing key interaction surfaces. These techniques are essential for understanding conformational changes.
CRISPR-Based Genetic Screens
Genome-wide CRISPR knockout or activation screens can identify genes that modulate FK506 sensitivity or FKBP function. Such screens have uncovered novel regulators of calcineurin signaling.
Proteomics and Interactomics
Affinity purification coupled with mass spectrometry (AP-MS) or proximity labeling (BioID) can map the interactome of FKBPs under FK506 treatment, revealing downstream effectors.
How CRISPR Can Be Used to Study GO:0005528 FK506 binding
Knockout
CRISPR knockout of FKBP genes (e.g., FKBP1A, FKBP1B) allows researchers to study loss-of-function phenotypes, such as altered T-cell activation or calcium handling. Knockout cell lines and animal models are valuable for target validation.
Point Mutation
Introducing point mutations in the FK506-binding domain of FKBPs can dissect residues critical for ligand binding or calcineurin interaction. For example, mutations in FKBP12 that abolish FK506 binding have been used to separate immunosuppressive from neuroprotective effects.
Knock-in
Knock-in of tagged FKBPs (e.g., GFP or APEX2) enables live-cell imaging and proximity labeling to study localization and interactions under physiological conditions.
Overexpression
Overexpression of FKBPs can reveal gain-of-function phenotypes, such as enhanced apoptosis resistance or altered steroid receptor signaling. This approach is useful for studying FKBP13 in cancer.
How EDITGENE Supports FK506 binding Research
Researchers studying FK506 binding-related genes often need to determine whether a candidate gene is causally involved in a specific pathway or disease. EDITGENE provides comprehensive CRISPR-based services to create precisely engineered cell models, enabling functional validation and drug discovery.
Contact EDITGENE today to design your custom CRISPR model for FK506 binding research.
Frequently Asked Questions About FK506 binding
What is FK506 binding?
FK506 binding is a molecular function (GO:0005528) where a protein binds to the immunosuppressant FK506, typically via an FKBP domain.
What genes are involved in FK506 binding?
Genes encoding FK506-binding proteins (FKBPs) include FKBP1A, FKBP1B, FKBP2, FKBP4, FKBP5, and others.
How does FK506 binding inhibit calcineurin?
The FKBP12-FK506 complex binds to calcineurin and inhibits its phosphatase activity, blocking T-cell activation.
What diseases are associated with FK506 binding proteins?
FKBPs are implicated in cancer, male infertility, neurodegeneration, and inflammatory diseases.
What is the role of FKBP12 in immunosuppression?
FKBP12 binds FK506 and forms a complex that inhibits calcineurin, leading to immunosuppression.
Can CRISPR be used to study FK506 binding?
Yes, CRISPR knockout, knock-in, and point mutation models are powerful tools to dissect FKBP gene function.
What are the research methods for studying FK506 binding?
Common methods include SPR, ITC, X-ray crystallography, CRISPR screens, and proteomics.
Is FK506 binding involved in male infertility?
Yes, FKBP12.6-mediated inhibition of sperm calcineurin by FK506 disrupts calcium homeostasis and causes male infertility.
What is the difference between FKBP12 and FKBP12.6?
FKBP12 (FKBP1A) and FKBP12.6 (FKBP1B) are distinct proteins with different tissue distributions and targets, such as ryanodine receptors.
How can I create a FKBP knockout cell line?
EDITGENE provides custom CRISPR knockout services for any FKBP gene to support your research.
Conclusion
FK506 binding (GO:0005528) is a fundamental molecular function mediated by FK506-binding proteins, which play critical roles in immunosuppression, calcium signaling, apoptosis, and disease. Understanding the mechanisms and genes involved is essential for developing targeted therapies. CRISPR-based models and advanced research methods continue to unravel the complexities of FK506 binding, offering new avenues for therapeutic intervention.
References
- 1. Annett S et al.. 2020. FK506 binding proteins and inflammation related signalling pathways; basic biology, current status and future prospects for pharmacological intervention.. Pharmacol Ther 215:107623 PMID: 32622856
- 2. Romano S et al.. 2010. FK506 binding proteins as targets in anticancer therapy.. Anticancer Agents Med Chem 10(9):651-6 PMID: 21182472
- 3. Akintade DD et al.. 2023. FK506-binding protein 2 (FKBP13) inhibit Bax-induced apoptosis in Saccharomyces cerevisiae (yeast).. Cell Biol Toxicol 39(3):719-728 PMID: 34342774
- 4. Xiao YF et al.. 2025. FK506 binding protein 12.6-mediated inhibition of sperm-specific calcineurin is essential for FK506-induced male infertility by disturbing the homeostasis of calcium and mitochondria.. Mol Biomed 6(1):149 PMID: 41428164
- 5. Liu F et al.. 2013. FK506-binding protein 12 ligands: a patent review.. Expert Opin Ther Pat 23(11):1435-49 PMID: 23957229
- 6. LeMaster DM et al.. 2024. Propagation of conformational instability in FK506-binding protein FKBP12.. Biochim Biophys Acta Proteins Proteom 1872(3):140990 PMID: 38142946
- 7. Liu J et al.. 1991. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes.. Cell 66(4):807-15 PMID: 1715244
- 8. Davies TH et al.. 2005. FKBP52.. Int J Biochem Cell Biol 37(1):42-7 PMID: 15381148
